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Abstract
Purpose This study assessed the effect of lurbinectedin, a highly selective inhibitor of oncogenic transcription, on the change 
from baseline in Fridericia’s corrected QT interval (∆QTcF) and electrocardiography (ECG) morphological patterns, and 
lurbinectedin concentration–∆QTcF (C-∆QTcF) relationship, in patients with advanced solid tumors.
Methods Patients with QTcF ≤ 500 ms, QRS < 110 ms, PR < 200 ms, and normal cardiac conduction and function received 
lurbinectedin 3.2 mg/m2 as a 1-h intravenous infusion every 3 weeks. ECGs were collected in triplicate via 12-lead digi-
tal recorder in treatment cycle 1 and 2 and analyzed centrally. ECG collection time-matched blood samples were drawn 
to measure lurbinectedin plasma concentration. No effect on QTc interval was concluded if the upper bound (UB) of the 
least square (LS) mean two-sided 90% confidence intervals (CI) for ΔQTcF at each time point was < 20 ms. C-∆QTcF was 
explored using linear mixed-effects analysis.
Results A total of 1707 ECGs were collected from 39 patients (females, 22; median age, 56 years). The largest UB of the 
90% CI of ΔQTcF was 9.6 ms, thus lower than the more conservative 10 ms threshold established at the ICH E14 guideline 
for QT studies in healthy volunteers. C-∆QTcF was better fit by an effect compartment model, and the 90% CI of predicted 
ΔQTcF at  Cmax was 7.81 ms, also below the 10 ms threshold of clinical concern.
Conclusions ECG parameters and C-ΔQTcF modelling in this prospective study indicate that lurbinectedin was not associ-
ated with a clinically relevant effect on cardiac repolarization.
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Introduction
Lurbinectedin (Zepzelca™), also known as PM01183, is a 
highly selective inhibitor of oncogenic transcription, with 
in vitro activity in the low nanomolar range [1]. Lurbi-
nectedin was approved in June 2020 by the U.S. Food and 
Drug Administration (FDA) to treat adult patients with 
metastatic small cell lung cancer with disease progression 
on or after platinum-based chemotherapy [2]. Lurbinect-
edin inhibits the transcription process through (i) its bind-
ing to CG-rich sequences, mainly located around promot-
ers of protein-coding genes; (ii) the irreversible stalling 
of elongating RNA polymerase II on the DNA template 
and its specific degradation by the ubiquitin/proteasome 
machinery; and (iii) the generation of DNA breaks and 
subsequent apoptosis [3].
Lurbinectedin is highly protein-bound. Based on 
in vitro studies, metabolism by cytochrome P450 (CYP) 
3A is the major clearance mechanism (data on file).
A population pharmacokinetic (PopPK) model [4] was 
developed with data from 443 cancer patients treated in six 
phase I and three phase II trials with 1-h intravenous (i.v.) 
infusion of lurbinectedin as a single agent or combined with 
other agents. The population estimate for total plasma clear-
ance was 11.2 L/h, corresponding to a blood CL of ~ 17 L/h, 
thus reflecting a low extraction ratio of 0.19. The popula-
tion estimate of apparent volume at steady state was 438 L. 
Inter-individual variability was moderate for all parameters, 
ranging from 20.9 to 51.2%. High α-1-acid glycoprotein 
and C-reactive protein, and low albumin reduced clearance 
by 28%, 20%, and 20%, respectively. Co-administration of 
cytochrome CYP3A inhibitors reduced clearance by 30%.
Predictable and reversible myelosuppression, particu-
larly neutropenia, is the most common limiting toxicity 
for lurbinectedin [5].
The non-clinical cardiovascular safety pharmacology 
evaluation of lurbinectedin consisted of in vitro and in vivo 
studies (data on file). The half maximal inhibitory concen-
tration  (IC50) determined for lurbinectedin in an in vitro 
hERG assay was 8.8 μM (6.9 μg/mL), far above from the 
maximum plasma concentration  (Cmax) reached in patients at 
therapeutic exposure (106 μg/mL). The in vivo studies were 
conducted in telemetered dogs and cynomolgus monkeys 
receiving a single i.v. bolus injection at the maximum toler-
ated dose. No effects were observed on lead II electrocar-
diogram (ECG) variables [PR, QT, and QTcF (Fridericia’s 
corrected QT)] and QTcV (QTc according to Van de Water’s 
formula) intervals, and QRS duration, ECG gross morphol-
ogy, or cardiac rhythm. Lurbinectedin-related cardiovascular 
changes were limited to mild decreases in blood pressure 
and increased heart rate (HR) associated with drug-induced 
nausea, vomiting, and/or pain.
To date, no cardiac toxicity concerns (i.e., contractibility, 
conduction/rhythm, or repolarization alterations) have been 
identified with lurbinectedin as a single agent.
Lurbinectedin is an antitumor drug that cannot be admin-
istered to healthy subjects. Therefore, QT evaluation had to 
be performed in a cancer patient population at a therapeutic 
dose. This QT evaluation study was nested into a basket 
clinical trial that was conducted to determine whether lur-
binectedin had any effects on the QT interval or any other 
ECG parameter, in patients with solid tumors at the rec-
ommended dose of 3.2 mg/m2 administered q3wk as a 1-h 
i.v. infusion, and not receiving any concomitant medica-
tion known to prolong QT interval. This population, with 
advanced solid cancer and several co-morbidities, allowed 
assessment of the QTc interval in a real-life population simi-
lar to the population for which therapeutic use of lurbinect-
edin is now approved.
Materials and methods
Patients were recruited at 12 investigational sites in the 
U.S. and Spain. The study protocol was submitted to the 
QT Interdisciplinary Review Team at the U.S. FDA, which 
considered the tested dose reasonable, and the ECG/phar-
macokinetic (PK) collection, sample size, and study design 
acceptable to fulfil the aims of the study. The study protocol 
was approved by the Independent Local Ethics Committee of 
each participating center and was conducted in accordance 
with the Declaration of Helsinki, Good Clinical Practice 
guidelines, and local regulations on clinical trials. Signed 
informed consent was obtained from all patients prior to any 
study-specific procedure.
Eligibility criteria
Eligibility criteria included: patients ≤ 65 years old; Eastern 
Cooperative Oncology Group performance status (ECOG 
PS) ≤ 1; 12-lead ECG recorded between day -10 and day 
-2 before first lurbinectedin administration, consistent with 
normal cardiac conduction and function, that was read by a 
central laboratory, showing sinus rhythm, heart rate (HR) 
between 45 and 100 beats per min (bpm), QTcF ≤ 500 ms 
(ms), QRS interval < 110 ms, and PR interval < 220 ms; 
systolic blood pressure 90-150 mmHg and diastolic blood 
pressure ≤ 90 mmHg; and grade ≤ 1 serum electrolyte levels 
according to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events (NCI-CTCAE) v.4.0.
Patients were excluded if they had heart rhythm distur-
bances (e.g., atrial fibrillation), unusual T wave and U wave 
morphology, personal or family history of long QT syn-
drome, ECG findings of complete left bundle branch block, 
permanent ventricular pacemaker, or Brugada syndrome; 
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significant ischemic coronary disease, New York Heart 
Association class III or IV congestive heart failure, myocar-
dial infarction, or unstable angina within the last 6 months; 
any skin condition likely to interfere with ECG electrode 
placement, or history of breast implant or thoracic sur-
gery likely to cause abnormality in electrical conduction; 
or prior exposure to anthracyclines at a cumulative dose of 
doxorubicin (or equivalent) > 450 mg/m2. Patients were also 
excluded if they were receiving QT-prolonging medication 
that could not be interrupted at least 48 h before each ECG 
assessment.
Study design
This was a QT evaluation study (EudraCT No. 2015-
000206-18; ClinicalTrials.gov: NCT02451007) performed 
at a subset of sites participating in a multicenter, open-label, 
exploratory, phase II basket clinical trial (EudraCT No: 
2014-003773-42; ClinicaTrials.gov: NCT02454972) con-
ducted in patients with selected advanced solid tumors. The 
schedule used in this QT evaluation study was that evaluated 
in the basket trial: lurbinectedin 3.2 mg/m2 given as a 1-h 
i.v. infusion q3wk.
Patients were instructed to avoid beverages containing 
alcohol or methylxanthine-containing products (e.g., choco-
late bars/candies and beverages like hot chocolate, coffee, 
tea, or colas) for 24 h before each ECG assessment; consume 
standard meals while at the study site, but avoid spicy foods 
and excessive food consumption.
Electrocardiogram acquisition and analysis
A screening ECG was collected between day -10 and day 
-2 before the first lurbinectedin infusion (day 1 of cycle 1) 
and transmitted to the central ECG laboratory to confirm the 
patient’s eligibility.
On day 1 of cycle 1, two baseline triplicate ECGs (three 
10-s digital ECGs in close succession) were collected: one 
before administration of prophylactic medication or pre-dose 
1, and the other after antiemetic prophylactic medication 
(palonosetron 0.25 mg i.v.) and before the start of the lurbi-
nectedin infusion or pre-dose 2 (also on cycle 2).
In cycle 1 and cycle 2, the following triplicate ECGs 
were collected 5–10 min before their time-matched PK time 
points: 5 min before end of the lurbinectedin infusion (EOI), 
30 min, 1, 3, 24, 72 (only on cycle 1), and 168 h after EOI.
A 12-lead automated digital ECG recorder [Mortara 
Instrument (Milwaukee, WI, USA) ELI-150 ECG 12-lead 
digital recorder] was provided by a third-party central 
ECG laboratory (eResearchTechnology, Inc., Philadel-
phia, PA, USA). Analysis and reporting of ECG data 
were performed by a limited number of skilled readers 
who were blinded to treatment time point. ECG review 
of a particular patient was performed by a single reader. 
Interval duration measurements were collected using 
computer-assisted caliper placements on three consecu-
tive beats. A cardiologist then verified the interval dura-
tions and performed the morphology analysis, noting any 
T-U wave complex compatible with an effect on cardiac 
repolarization. The ECG analysis was conducted in Lead 
II or in Lead V5 if Lead II was not analyzable. If Lead V5 
was not analyzable, then Lead V2 was used, and followed 
by the most appropriate lead if necessary. The mean of 
triplicate ECG measures at each time point for each patient 
was used for analyses.
QT correction methods
Fridericia’s formula [6] is currently considered the most 
accurate method for correcting the effect of HR on QT inter-
val [7], and was used as the main method for HR correction 
for QT (QTcF). Nevertheless, graphical inspection of QTcF 
and QT corrected by Bazett’s formula (QTcB) [8] versus RR 
interval plots and statistical comparison of resulting squared 
linear regression slopes (R2) was performed.
Pharmacokinetic assessments
Pharmacokinetic (PK) profiles of lurbinectedin were 
obtained on cycle 1 and cycle 2. Following ECGs’ acqui-
sition, blood samples were collected into K3EDTA tubes. 
Tubes were gently inverted several times and centrifuged at 
2000 × g for 10 min at 4 °C to separate the plasma.
Plasma concentrations of lurbinectedin were measured 
by a validated liquid chromatography–mass spectrometry 
assay (Dynakin S.L., Spain), with ranges of 0.1–50 μg/L. 
The within- and between-day precisions ranged from 2.7 to 
12.9% and from 5.1 to 10.7%, respectively. The within- and 
between-day accuracy (bias) ranged from 10 to 12% and 
from 5 to 6%, respectively.
Datasets were prepared using SAS Enterprise Guide 
v.7.11 HF3 (SAS Institute Inc., Cary, NC, USA). Non-com-
partmental PK parameters were determined using Phoenix 
WinNonlin v.6.3 (Certara, USA). Non-linear mixed-effect 
modelling was performed in NONMEM v.7.3.0 (GloboMax 
LLC, Hanover, MD, USA). Graphical and all other statisti-
cal analyses were performed in R v.3.2.5 (R Foundation for 
Statistical Computing, Vienna, Austria).
Safety assessment
Cardiac adverse events (AEs) observed in the period of this 
QT evaluation study were evaluated and graded according to 
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the National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI-CTCAE), v.4 and coded using the 
Medical Dictionary for Regulatory Activities (MedDRA) 
v.16.0. Laboratory results of particular relevance (i.e., 
changes in albumin, calcium, potassium, or magnesium) 
were graded according to the NCI-CTCAE v.4.
Endpoints
The primary endpoint was the change in QTc corrected by 
the Fridericia’s formula (ΔQTcF) between each scheduled 
post-baseline ECG time point and baseline at cycle 1. A 
patient was considered evaluable for the primary endpoint 
if he/she had baseline and one or more post-baseline ECG 
assessments.
Secondary endpoints were the ΔQTcF/lurbinectedin 
plasma concentration relationship, and change in other ECG 
parameters (i.e., HR, QRS, and PR).
Statistical methods
“By time point” analysis
The primary comparison was ΔQTcF at each ECG time 
point. A non-inferiority criterion of 20 ms was used to estab-
lish the absence of post-baseline QTc prolongation when 
compared to baseline. An analysis of variance model with 
mixed effects was fitted, with ΔQTc data as the dependent 
variable and ECG time point as the fixed effects, and patient 
as random effect.
Using the estimated least square means (LSM) and intra-
patient standard deviation (Std) obtained from this model, a 
two-sided 90% confidence interval (CI) was calculated for 
each LSM ΔQTc. Non-inferiority was to be concluded if the 
upper bound (UB) of the one-sided 95% CI fell below 20 ms 
at each ECG time point.
Sample size calculation
Assuming that the intra-subject Std for change from baseline 
in QTc (ΔQTc) is 30 ms and that the true difference between 
means is 5 ms, a sample size of at least 25 evaluable patients 
in more than 80% of the scheduled post-baseline ECG time 
points t was planned to have 80% power to show that the UB 
of the two-sided 90% CI (UB of the one-sided 95% CI) for 
mean ΔQTc at each ECG time point was < 20 ms. Approxi-
mately 35 patients were to be enrolled to ensure that at least 
25 evaluable patients completed all required assessments.
Concentration–QTc analysis
C–ΔQTcF was assessed using a linear mixed-effects 
(LME) model, as proposed by Garnett et al. [9]. As the data 
available came from a single arm study, the LME model was 
characterized by the intercept ( 𝜃1 ) and the slope ( 𝜃2 ), and 
their corresponding variabilities.
where Cij is the model-predicted lurbinectedin total plasma 
concentrations (or the lurbinectedin concentrations in the 
effect compartment if a hysteresis is present), and 𝜂1,i and 
𝜂2,i are the random effects associated with the intercept term 
𝜃1 and the slope term 𝜃2 , respectively, and are assumed to be 
exponential, independent, and normally distributed. Further-
more, 𝜖ij is the random residual variability, assumed to be 
an additive, independent, and normally distributed random 
variable. In the absence of placebo data, the unstructured 
placebo model consisting on the fixed effect parameters 
accounting for treatment-specific intercept (TRT ), mean 
ΔQTcF at each time point evaluated (TIME), and baseline 
QTc was not included in the model. Based on the fact that 
ECG and PK assessments in this study were performed on 
two occasions (cycle 1 and cycle 2), the effect of cycle 𝜃3 
was also assessed in the models. To select the model for 
the C-ΔQTcF analysis (i.e., direct or indirect), a potential 
delay of the ΔQTcF effect relative to plasma concentrations 
(hysteresis) was graphically and statistically assessed, as 
proposed by Darpo et al. [10]. To enable an adequate com-
parison of the model fit between the direct effect model and 
the effect compartment model, the model-based predicted 
total plasma concentrations at central compartment (“direct” 
model) and at the effect compartment (“indirect” model) 
were used. These were based on the individual PK param-
eters, obtained through a maximum a posteriori estimation 
based on the individual total plasma concentration avail-
able for each subject and a population PK model previously 
developed [4].
The assumption of linearity of the C–ΔQTcF relationship 
was assessed by goodness-of-fit plots. Besides, a model with 
an empirical quadratic term of total plasma concentration was 
fitted and the significance of the quadratic term was tested. In 
case of the absence of trends in the goodness-of-fit plots and a 
non-significant quadratic term, the C–∆QTcF relationship was 
considered linear; otherwise, the relationship was considered 
non-linear.
The predicted effect of lurbinectedin on ΔQTcF was esti-
mated at the  Cmax geometric mean either at the central or at the 
effect compartment in the first two cycles following the admin-
istration of 3.2 mg/m2 i.v. over 1-h q3wk and was calculated as 
the estimated intercept ( 𝜃1,Est ) plus the product of the estimated 












⋅ Cij + 𝜃3 ⋅ Cycle + 𝜖ij,
(2)Estimated Mean ΔQTcF(C) = 𝜃1,Est + C × 𝜃2,Est.
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Two-sided 90% confidence intervals (CIs) of the estimated 














 is the covari-
ance of intercept and slope; t is the critical value determined 
from the t-distribution; DF is the degrees of freedom; SE is 
the standard error; and CI is the confidence interval.
To exclude a prolongation of QT for lurbinectedin 
assuming that there is no placebo effect, the upper bound 
(UB) of the 2-sided 90% CI of the model-predicted mean 
ΔQTcF had to be lower than 10 ms (threshold set at the 
ICH E14 Q&A R3 [11]), at the  Cmax geometric mean 
obtained after administration of the clinically relevant 
dose of 3.2 mg/m2 i.v. over 1-h q3wk.
The  Cmax geometric mean either at the central or at the 
effect compartment, at which UB 90% CI of the model-
predicted mean ΔQTcF would be above 10 ms and 20 ms 
thresholds, was also estimated according to the formulas 
provided above.
Results
From August 2015 to June 2016, a total of 39 evaluable 
patients were included in the study. At the majority of 
post-baseline assessments, data were available from at 
least 35 patients. Most of the 39 patients (n = 32; 82.1%) 
completed all QT assessments; four patients discontinued 
due to patient refusal, and three patients due to disease 
progression (one of them died during the study period).
Patient characteristics
Main patient characteristics are summarized in Table 1. 
Twenty-two of the 39 included patients (56.4%) were female. 
Median age was 56 years (range 28–65 years). Blood pres-
sure at study entry was within the limits stated in the inclu-
sion criteria. Performance status score was 0 (n  = 17; 43.6%) 
or 1 (n  = 22; 56.4%). ECG at baseline was normal (n = 29; 
74.4%) or without significant abnormalities (n  = 10; 25.6%). 
Left-ventricular ejection fraction (LVEF) at baseline was 
within the normal institutional range in all patients.
The most common tumor types were endometrial car-
cinoma (n  = 9; 23.1%); head and neck carcinoma (n = 6; 



















90%CI = Estimated Mean ΔQTc(C) ± t(0.95, DF) × Estimated SE,
cancer (n  = 5 each; 12.8%). Six patients had previously 
received anthracyclines in the neoadjuvant (n = 3) or in 
the advanced setting (n  = 4).
With respect to cardiac events at baseline, a 55-year-
old female patient diagnosed with endometrial carcinoma 
had grade 1 diastolic dysfunction, with normal ECG and 
LVEF values.
Heart rate correction
The performance of Fridericia’s heart rate (HR) correction 
was compared to that of Bazett’s by graphical analysis of the 
plots of QT/QTc versus RR intervals (Fig. 1). The Frideri-
cia’s formula corrected for HR reasonably well, with a slight 
tendency to over-correct resulting QTc values. In contrast, 
the Bazett’s formula showed a marked over-correction on 
QT values. QTc versus RR data for both correction methods 
were also compared by calculating the mean of the  R2 (95% 
CIs): − 0.009 (− 0.018 to − 0.001) for QTcF and − 0.105 
(− 0.115 to − 0.095) for QTcB. The lower QTcF value with 
a not significant p value different from zero demonstrated 
that QTcF was less dependent on HR (slope closer to zero) 
than QTcB, then supporting the selection as per protocol of 
Fridericia as the primary HR-correction formula.
Change in QTcF (ΔQTCF)
No patients had pre-dose 2 QTcF value ≥ 20 ms longer than 
the pre-dose 1, thus ruling out a relevant effect of prophylac-
tic medication on QTcF. As a minimum difference (1.3 ms) 
was observed between mean pre-dose 1 and mean pre-dose 
2 values, the mean of both was used as baseline for the cal-
culation of ΔQTcF.
LSM of ΔQTcF and two-sided 90% CIs are depicted and 
summarized in Fig. 2. The maximum LSM ΔQTcF occurred 
3 h after the end of cycle 2 infusion (5.39 ms; 90% CI 1.17, 
9.60) and, at other time points, LSM ΔQTcF were ≤ 3.3 ms, 
and UB of the 90% CI were < 6.6 ms. Therefore, the UB 
90% CI at all time points were less than the pre-specified 
cut-off of 20 ms; then, the absence of QTc prolongation by 
the treatment can be concluded.
ΔQTcF/lurbinectedin plasma concentration
Mean non-compartmental PK parameters in cycle 1 of the 39 
evaluable patients were comparable to that from the popula-
tion PK model of lurbinectedin containing data from more 
than 400 patients [4]. Basically, mean (coefficient of varia-
tion) clearance was 11.8 L/h (53.3%) and volume of distribu-
tion was 347.7 L (51.0%) in the 39 patients, while values of 
these typical PK parameters were 11.2 L/h and 438.4 L in 
the population PK analysis, respectively. Mean lurbinectedin 
 Cancer Chemotherapy and Pharmacology
1 3
plasma concentration was very similar in cycles 1 and 2 
(Fig. 3).
Time-matched profiles of mean ΔQTcF and lurbinect-
edin observed total plasma concentrations are depicted 
in Fig. 4. The largest mean ΔQTcF was 4.69 ms (at 4 h 
after the start of infusion on cycle 2), thus not exceeding 
the 5 ms threshold at any time point (Table 2). There-
fore, the first statistical criterion for hysteresis, according 
to Darpo et al. [10], was unmet. No delay was seen in 
cycle 1 between  Umax (time after the administration of a 
drug when the largest mean ΔQTcF is reached) (0.92 h) 
and  Tmax (0.92 h), while there was a 3.08 h difference in 
cycle 2 between  Umax (0.92 h) and  Tmax (4 h), thus meet-
ing, at least partially, the second criterion for hysteresis. 
However, in cycle 2, the one-sided one-sample Wilcoxon 
test for the difference between ΔQTcF at  Tmax (1.54 ms 
at 0.92 h) and at  Umax (4.69 ms at 4 h) was not significant 
at 1% level (p value = 0.1749); therefore, the third crite-
rion for hysteresis was not fulfilled. As the presence of a 
delayed effect of lurbinectedin on the QT interval could 
not be fully ruled out, direct and indirect effect models 
were developed to identify and select the best fit to the 
data.
Table 1  Patient characteristics 
at baseline (n = 39)
bpm beats per minute, BSA body surface area, ECG electrocardiogram, ECHO echocardiography, ECOG 
PS Eastern Cooperative Oncology group performance status, LVEF left-ventricular ejection fraction, 






Median (range) 56 (28–65)
 28–42 years 5 12.8
 43–65 years 34 87.2
Weight (kg), median (range) 76.0 (42.9–115.0)
Height (cm), median (range) 169.0 (149.0–187.0)
BSA  (m2), median (range) 1.9 (1.4–2.3)
Heart rate (bpm), median (range) 76 (56-103)
Systolic blood pressure (mmHg), median (range) 123 (93–147)
Diastolic blood pressure (mmHg), median (range) 74 (56–86)






 Non-significant abnormalities 10 25.6
LVEF, median (range)
 ECHO (n  = 35) 62.0 (50.0–75.0)
 MUGA (n  = 4) 65.5 (56.0–67.0)
Tumor type
 Endometrial carcinoma 9 23.1
 Head and neck carcinoma 6 15.4
 Neuroendocrine tumors 5 12.8
 Small cell lung cancer 5 12.8
 Biliary tract carcinoma 4 10.3
 Ewing’s family of tumors 3 7.7
 Germ cell tumor 3 7.7
 BRCA 1/2-associated metastatic breast carcinoma 2 5.1
 Carcinoma of unknown primary site 2 5.1
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Modelling of concentration-ΔQTcF
A model with random effects in slope and intercept and a 
correlation parameter between these random effects was 
retained as the final direct model:
The slope was estimated as 0.072 ms·L/μg, with an 
intercept of − 1.47 ms (Table 3). Observed and predicted 
values showed a good agreement. The goodness-of-fit for 
the residuals did not deviate substantially from normal-
ity and no trend was seen in the weighted residuals plots, 
which showed normal random scatter around zero, without 












Nonetheless, an effect compartment model with random 
effects in slope and intercept showed a major improvement 
over the corresponding direct effect model. The inclusion of 
a correlation parameter between the random effects of the 
slope and the intercept showed an additional improvement. 
The addition of a cycle effect or a quadratic term to this 
model was not significant. Therefore, the model selected as 
final was as follows:
where Ceij is the lurbinectedin concentration at the effect 
compartment  (Table  3). The slope was estimated as 
0.289 ms L/μg, the intercept as − 3.95 ms, and the equilibra-












Fig. 1  Overlay of mixed-effects model estimates (solid red line) with 
two-sided 90% CIs (dashed red lines) and observed patient data for 
QT, Fridericia’s corrected QT (QTcF) and Bazett’s corrected QT 
(QTcB) vs. time-matched RR. Each open circle represents an individ-
ual observation at each time point
Fig. 2  Least squares mean and upper bound (UB) of two-sided 90% 
confidence intervals (CI) of change in Fridericia’s corrected QT 
(ΔQTcF) at each time point in cycle 1 and cycle 2, with correspond-
ing values below the horizontal axis. Horizontal dotted red lines 
represent the 10 and 20 ms threshold criteria. Times at the horizon-
tal axis are after the end of lurbinectedin infusion, saved for those 
marked with * and ** which are before the end and before the start of 
lurbinectedin infusion, respectively
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between ΔQTcF and lurbinectedin concentration at the effect 
compartment is shown in Fig. 5.
The appropriateness of the indirect model was also 
explored graphically, without any signals suggesting non-
linearity (Fig. 6).
The predicted ΔQTcF at  Cmax of lurbinectedin at the 
effect compartment (30.53 μg/L) at the recommended dose 
was 4.87 ms (90% CI 1.94–7.81). With the direct effect 
model  (Cmax of 116.62 μg/L), ΔQTcF was 6.93 ms (90% 
CI 4.96–8.90). Therefore, regardless of the direct or indi-
rect effect of lurbinectedin concentrations, ΔQTcF at the 
recommended dose is not expected to exceed 10 ms.
Moreover,  Cmax of lurbinectedin at the effect compartment 
associated with the thresholds of 10 and 20 ms UB 90% CI 
of ΔQTcF were estimated for the delayed effect model as 
36.18 and 61.94 μg/L, respectively. Based on  Cmax at the rec-
ommended dose (30.53 μg/L), 36.18 and 61.94 μg/L would 
correspond to lurbinectedin dose of 3.8 mg/m2 and 6.5 mg/
m2, respectively, which represent a 1.21- and 2.03-fold 
increase. With the direct effect model,  Cmax associated with 
those thresholds were estimated as 129.05 and 241.25 μg/L, 
respectively, corresponding to doses of 3.6 and 6.6 mg/m2.
Change in other ECG parameters
As with the QTc interval, mean (± Std) values of other 
ECG parameters remained constant along the study except 
for HR, which showed a transient increase with the highest 
change from baseline at 3 h after the end of infusion: 16.7 
(± 11.0) bpm in Cycle 1 and 17.5 (± 11.7) bpm in cycle 2. 
Mean change from baseline of PR interval and QRS duration 
showed limited fluctuation across all time points and cycles, 
with minimal variations between the lowest and largest mean 
values of 7.8 ms and 2.5 ms, respectively.
Safety
No relevant cardiac safety findings were observed within 
the QT evaluation study period, except for one case of grade 
3 hypokalemia (potassium of 2.5 mmol/L) occurred in a 
patient with grade 4 respiratory failure and aspiration not 
related to the study treatment, which was resolved after i.v. 
electrolyte replacement.
Discussion
This study was designed to evaluate the potential effect of 
lurbinectedin at the recommended dose (3.2 mg/m2 given 
as a 1-h i.v. infusion q3wk) on the QT interval duration fol-
lowing, to the extent feasible, current regulatory standards 
described in the ICH E14 guideline [12]. Possible immediate 
or delayed effect for delaying cardiac ventricular repolariza-
tion was assessed through centralized, blinded, third-party 
evaluation of changes in QTc during treatment at thirteen 
post-baseline time points. Thirty-nine evaluable patients 
were included in this study and they provided a total of 1707 
Fig. 3  Lurbinectedin plasma concentrations vs. time on cycle 1 and 
cycle 2. Blue circled and green squared dots represent lurbinectedin 
plasma concentrations in cycles 1 and 2, respectively. The shaded 
green area and the green line represent the 90% prediction interval 
and the median of simulated lurbinectedin plasma concentrations 
when given at 3.2 mg/m2 (from the population PK model) [17]
Fig. 4  Mean ΔQTcF (red lines, right y-axis) and plasma observed 
lurbinectedin concentration (blue lines, left y-axis), by time point, in 
cycle 1 (upper panel) and cycle 2 (bottom panel)
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ECGs, with most of the scheduled ECG assessments avail-
able in at least 35 patients.
The method for heart rate correction (Fridericia) selected 
for the primary endpoint in this study was found to be more 
accurate than the Bazett’s correction method  (R2 for QTcF 
and QTcB vs. RR of − 0.009 and − 0.105, respectively), 
which has been already reported to over-correct the QT 
interval with increasing HR, resulting in false positives for 
QTc prolongation [13], and is, no longer, warranted unless 
used for specific reasons [12]. Moreover, the Fridericia’s 
correction tends to be even more reliable and accurate than 
the Bazett’s correction when compensating for changes in 
heart rate induced by a drug or by clinical conditions. This 
is especially relevant when the heart rate increases during 
therapy as compared with baseline [7].
The primary endpoint analysis in this study consisted of a 
“by time point” analysis of change in QTcF (ΔQTcF). UBs 
Table 2  Mean (Stdv) ΔQTcF and observed lurbinectedin concentration by time point and Cycle  (Umax,  Tmax, and  Cmax in cycle 1 and cycle 2 in 
italics)
*Hours after start of infusion
ΔQTcF variation in QTc corrected according to Fridericia’s formula, Cmax maximum plasma concentration; Tmax, time after the administration of 
a drug when the Cmax is reached; Umax time after the administration of a drug when the largest mean ΔQTCF is reached
Cycle 1 Cycle 2
Time point (h)* 0.92 1.5 2 4 25 73 169 0.92 1.5 2 4 169





















































Fig. 5  Change from baseline in Fridericia’s corrected QT 
(ΔQTcF) vs. lurbinectedin concentration at effect compart-
ment.  The observed  ΔQTcF  have been grouped into deciles of 
the  predicted concentrations at effect compartment  and the aver-
age  observed  ΔQTcF  (black dots) have been plotted at the aver-
age  predicted concentrations in each decile  with two-sided 90% 
CI. Solid black line and grey area denote the model-predicted ΔQTcF 
with two-sided 90% confidence intervals (CI) as a function of lurbi-
nectedin concentration at the effect compartment. Vertical dashed 
green, red, and blue lines indicate the maximum plasma concentra-
tion  (Cmax) geometric mean of lurbinectedin associated with the 
3.2  mg/m2 dose,  Cmax  geometric mean of lurbinectedin associated 
with the 3.8 mg/m2 dose at which upper bound of the two-sided 90% 
confidence interval of the ΔQTcF is 10 ms (red line), and Cmax geo-
metric mean of lurbinectedin associated with the 6.5 mg/m2 dose at 
which upper bound of the two-sided 90% confidence interval of the 
ΔQTcF is 20 ms (blue line)
Table 3  Parameter estimates for direct model and delayed effect 
model
Keo, equilibration rate constant; MVOF minimum value of the objec-
tive function; RSE relative standard error
MVOF Final direct model Final delayed effect 
model
2550 2459
Parameter Estimate RSE (%) Estimate RSE (%)
Intercept, ms − 1.47 8.18 − 3.95 7.22
Slope, ms L/μg 0.072 12.2 0.289 17.6
Keo, 1/h – 0.298 0.292
Residual variability (%) 9.25 3.83 8.36 3.92
Variability in intercept (%) 165 13.1 105 13.3
Variability in slope (%) 14.0 73.9 29.8 40.3
Correlation intercept-
slope (%)
− 49.5 29.4 − 63.5 25.8
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of the two-sided 90% CIs of ΔQTcF at any time point did 
not exceed the pre-defined 20 ms non-inferiority margin, 
i.e., the threshold typically employed for oncology agents 
[7]. The largest UB of 90% CI corresponding to 3 h after end 
of infusion at Cycle 2 was 9.6 ms, thus lower than the more 
conservative 10 ms threshold established in the ICH E14 
guideline for thorough QT studies in healthy volunteers [12]. 
Of note, in a human mass balance study (EudraCT No. 2016-
000800-27), the exposure of all lurbinectedin metabolites 
when compared to that of the parent compound was con-
siderably lower (10% or less) and their half-lives and tmax 
were similar or even shorter, thus ruling out their contribu-
tion to the apparent 3-h delay of the largest UB 90% CI of 
ΔQTcF. No single value was above the reference limit values 
of concern (namely, QTcF > 480 ms and ΔQTcF > 60 ms) in 
any of the 39 evaluable patients. Therefore, a large effect of 
lurbinectedin on QT interval is confirmed as very unlikely.
In a secondary endpoint analysis, the relationship 
between ΔQTcF and time-matched exposure to lurbinect-
edin was evaluated; this analysis aimed to improve the 
evaluation by means of gathering in the same model all 
ΔQTcF values collected across the wide range of lurbi-
nectedin plasma concentrations. The fit between lurbi-
nectedin concentrations and ΔQTcF was improved when 
an effect compartment was added, and a slightly positive 
slope (0.289 ms·L/μg) was found between the concentra-
tion at the effect compartment and ΔQTcF (of note, lowest 
lurbinectedin concentrations from the terminal phase were 
related to negative mean ΔQTcF values, thus leading to 
a likely overestimation of the resulting positive value). 
The UB 90% CI of ΔQTcF was estimated to be 7.81 ms 
at  Cmax at the effect compartment, following the recom-
mended dose. As proposed by Darpo et al. [10], and later 
acknowledged at the ICH E14 Q&A R3 [12], a clinically 
relevant QT effect can be excluded when the UB of the 
two-sided 90% CI for the QTc effect is below 10 ms at 
plasma levels of the compound that can be observed at 
the highest clinically relevant exposure, to conclude that 
an expanded ECG safety evaluation during later stages of 
drug development is not needed. According to this crite-
rion, lurbinectedin is not associated with an effect of con-
cern on cardiac repolarization. Furthermore, based on the 
relationship established, a dose of 6.7 mg/m2 i.v. over 1-h 
q3wk is the expected maximal dose that will not exceed 
the threshold of 20 ms, established for oncology drugs.
For compounds that increase or decrease heart rate more 
than 10 bpm, subject-specific QT–RR correction methods 
to account for heart rate effects are encouraged [14]. The 
superiority of these methods over the Fridericia formula rely 
on the collection of either drug-free QT data in all subjects 
over a wide range of heart rates, which implies the inclusion 
of a baseline (drug-free) day, or 5-min history of preceding 
RR intervals for each QT interval measurement by means of 
Holter ECGs. To avoid longer inpatient confinement or trou-
blesome procedures, the present study did not incorporate 
any of these assessments, which may suppose a limitation 
on the correction of heart rate effects.
In this study, a modest increase of mean heart rate (maxi-
mum ΔHR of 16.7 bpm in Cycle 1 and 17.5 bpm in Cycle 2) 
affecting an ample number of patients (44% in Cycle 1 and 
49% in Cycle 2, with ΔHR > 25%) was typically detected 
at 4 h after the start of the 1-h infusion, thus not related to 
 Cmax, and baseline values were recovered in the next assess-
ments. This finding had been already reported in previous 
clinical trials. Moreover, a similar pattern is also described 
for trabectedin, the first-in-class RNA polymerase II 
Fig. 6  Diagnostic plots of the linear mixed effect model for the 
delayed concentration–ΔQTcF relationship. Upper panels: observed 
vs. population (left panel) and individual (right panel) predicted plots. 
Red dashed line line of unity, blue line loess smoother. Middle pan-
els: normalized prediction distribution errors (NPDE) vs population 
predicted (left panel) and time (right panel). Black line line of unity, 
blue line loess smoother, dashed lines upper and lower limits. Lower 
panels: histogram (left panel) and QQ plots (right panel) for normal-
ized prediction distribution errors (NPDE). Red line probability den-
sity function from the data, dashed red line mean, black line probabil-
ity density function from a Gaussian distribution based on the data
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inhibitor; in a dedicated QT evaluation study with this com-
pound given as a 3-h i.v. infusion [15], heart rate increased 
slightly, with largest increases from baseline at 4 h after the 
start of infusion, and declining to values similar to baseline 
at 24 h. No clinical consequence was observed with either 
drug. Trabectedin, an approved therapy for the treatment of 
soft-tissue sarcoma and ovarian cancer, is known to have a 
low cardiac risk profile [16]. This transient increase in heart 
rate observed with both compounds, whether direct (e.g., 
sympathomimetic effect) or indirect (e.g., vasodilatation, 
autonomic tone or anxiety), is of unknown significance.
No significant effects either on atrioventricular conduc-
tion or on depolarization, as measured by mean changes in 
PR and QRS intervals, were observed. No adverse events 
suggestive of proarrythmic potential were reported.
In conclusion, ECG parameters and concentration–ΔQTc 
modelling in this prospective study indicate that lurbinect-
edin is not associated with a clinically relevant effect on 
cardiac repolarization. Hence, lurbinectedin treatment is not 
likely to be associated with signals of clinical concern in the 
development of torsades de pointes/sudden death.
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